2024 Q1 Form 10-K Financial Statement
#000095017024018447 Filed on February 22, 2024
Income Statement
Concept | 2024 Q1 | 2023 Q4 | 2023 |
---|---|---|---|
Revenue | $88.64M | $108.4M | $380.8M |
YoY Change | 24.1% | 395.54% | 1612.94% |
Cost Of Revenue | $5.945M | $9.360M | $25.44M |
YoY Change | 12.53% | 231.8% | 750.02% |
Gross Profit | $82.70M | $99.09M | $355.3M |
YoY Change | 25.03% | 419.77% | 1747.2% |
Gross Profit Margin | 93.29% | 91.37% | 93.32% |
Selling, General & Admin | $57.76M | $52.24M | $188.4M |
YoY Change | 31.25% | 27.9% | 48.16% |
% of Gross Profit | 69.84% | 52.72% | 53.01% |
Research & Development | $36.61M | $44.91M | $128.2M |
YoY Change | 51.32% | 96.88% | 37.17% |
% of Gross Profit | 44.27% | 45.33% | 36.07% |
Depreciation & Amortization | $315.0K | $298.0K | $1.088M |
YoY Change | 54.41% | 63.74% | 123.41% |
% of Gross Profit | 0.38% | 0.3% | 0.31% |
Operating Expenses | $94.37M | $97.16M | $316.5M |
YoY Change | 38.37% | 52.62% | 43.51% |
Operating Profit | -$122.1M | $1.934M | $38.80M |
YoY Change | 5848.86% | -104.34% | -119.27% |
Interest Expense | $4.326M | $4.371M | $16.16M |
YoY Change | 16.35% | 38.45% | 276.49% |
% of Operating Profit | 226.01% | 41.63% | |
Other Income/Expense, Net | $3.579M | $171.0K | $15.50M |
YoY Change | 3.56% | -124.82% | 314.3% |
Pretax Income | -$118.6M | $6.476M | $54.30M |
YoY Change | -8549.82% | -115.37% | -127.48% |
Income Tax | $242.0K | $1.745M | $5.026M |
% Of Pretax Income | 26.95% | 9.26% | |
Net Earnings | -$118.8M | $4.731M | $49.27M |
YoY Change | -7652.0% | -111.08% | -124.84% |
Net Earnings / Revenue | -134.01% | 4.36% | 12.94% |
Basic Earnings Per Share | -$1.75 | $0.73 | |
Diluted Earnings Per Share | -$1.75 | $0.07 | $0.70 |
COMMON SHARES | |||
Basic Shares Outstanding | 67.78M | 67.52M | 67.23M |
Diluted Shares Outstanding | 67.85M | 69.99M |
Balance Sheet
Concept | 2024 Q1 | 2023 Q4 | 2023 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $373.3M | $371.4M | $371.4M |
YoY Change | 7.99% | 7.04% | 7.04% |
Cash & Equivalents | $170.6M | $170.2M | $170.2M |
Short-Term Investments | $202.7M | $201.2M | $201.2M |
Other Short-Term Assets | $16.89M | $14.93M | $14.93M |
YoY Change | 32.48% | 47.64% | 47.64% |
Inventory | $0.00 | $38.32M | $38.32M |
Prepaid Expenses | |||
Receivables | $20.35M | $40.05M | $40.05M |
Other Receivables | $0.00 | $0.00 | $0.00 |
Total Short-Term Assets | $410.5M | $464.7M | $464.7M |
YoY Change | 5.52% | 21.6% | 21.6% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $2.459M | $2.686M | $6.411M |
YoY Change | -3.91% | 2.87% | -21.19% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $493.0K | $701.0K | $46.38M |
YoY Change | 5.79% | 50.43% | 3813.67% |
Total Long-Term Assets | $6.923M | $52.79M | $52.79M |
YoY Change | -63.38% | 466.39% | 466.39% |
TOTAL ASSETS | |||
Total Short-Term Assets | $410.5M | $464.7M | $464.7M |
Total Long-Term Assets | $6.923M | $52.79M | $52.79M |
Total Assets | $417.5M | $517.5M | $517.5M |
YoY Change | 2.33% | 32.19% | 32.19% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $21.45M | $22.06M | $22.06M |
YoY Change | 99.19% | 252.58% | 252.58% |
Accrued Expenses | $67.87M | $57.72M | $59.98M |
YoY Change | 75.15% | 43.05% | 48.64% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $91.64M | $82.04M | $82.04M |
YoY Change | 77.54% | 76.02% | 76.02% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | $1.382M | $1.980M | $1.980M |
YoY Change | -62.59% | -53.27% | -53.27% |
Total Long-Term Liabilities | $1.382M | $1.980M | $1.980M |
YoY Change | -62.59% | -53.27% | -53.27% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $91.64M | $82.04M | $82.04M |
Total Long-Term Liabilities | $1.382M | $1.980M | $1.980M |
Total Liabilities | $93.02M | $84.02M | $84.02M |
YoY Change | 68.18% | 65.25% | 65.25% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$423.7M | -$304.9M | |
YoY Change | 20.16% | -13.9% | |
Common Stock | $748.3M | $738.2M | |
YoY Change | 6.09% | 6.23% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $324.4M | $433.4M | $433.4M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $417.5M | $517.5M | $517.5M |
YoY Change | 2.33% | 32.19% | 32.19% |
Cashflow Statement
Concept | 2024 Q1 | 2023 Q4 | 2023 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$118.8M | $4.731M | $49.27M |
YoY Change | -7652.0% | -111.08% | -124.84% |
Depreciation, Depletion And Amortization | $315.0K | $298.0K | $1.088M |
YoY Change | 54.41% | 63.74% | 123.41% |
Cash From Operating Activities | -$489.0K | $13.55M | $11.92M |
YoY Change | -90.36% | -127.26% | -106.63% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $67.00K | $351.0K | $1.241M |
YoY Change | -73.2% | -43.39% | -50.87% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $886.0K | $21.28M | $93.29M |
YoY Change | -98.42% | -109.35% | -139.45% |
Cash From Investing Activities | $819.0K | $20.92M | $92.05M |
YoY Change | -98.54% | -109.17% | -138.52% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 131.0K | 233.0K | 3.543M |
YoY Change | -87.4% | -99.9% | -99.18% |
NET CHANGE | |||
Cash From Operating Activities | -489.0K | 13.55M | 11.92M |
Cash From Investing Activities | 819.0K | 20.92M | 92.05M |
Cash From Financing Activities | 131.0K | 233.0K | 3.543M |
Net Change In Cash | 351.0K | 34.71M | 107.7M |
YoY Change | -99.33% | -175.92% | 736.96% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$489.0K | $13.55M | $11.92M |
Capital Expenditures | $67.00K | $351.0K | $1.241M |
Free Cash Flow | -$556.0K | $13.20M | $10.68M |
YoY Change | -89.55% | -126.23% | -105.85% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2023 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2023 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001658551 | |
CY2023 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
CY2023Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2022Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2023Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2023Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2023 | us-gaap |
Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
|
http://fasb.org/us-gaap/2023#ProductMember | |
CY2022 | us-gaap |
Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
|
http://fasb.org/us-gaap/2023#ProductMember | |
CY2023 | us-gaap |
Defined Benefit Plan Tax Status Extensible List
DefinedBenefitPlanTaxStatusExtensibleList
|
http://fasb.org/us-gaap/2023#QualifiedPlanMember | |
CY2022 | us-gaap |
Defined Benefit Plan Tax Status Extensible List
DefinedBenefitPlanTaxStatusExtensibleList
|
http://fasb.org/us-gaap/2023#QualifiedPlanMember | |
CY2023 | dei |
Document Type
DocumentType
|
10-K | |
CY2023 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
CY2023 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-12-31 | |
CY2023 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2023 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | |
CY2023 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2023 | dei |
Entity File Number
EntityFileNumber
|
001-41199 | |
CY2023 | dei |
Entity Registrant Name
EntityRegistrantName
|
Amylyx Pharmaceuticals, Inc. | |
CY2023 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | |
CY2023 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
46-4600503 | |
CY2023 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
43 Thorndike St. | |
CY2023 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Cambridge | |
CY2023 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
MA | |
CY2023 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
02141 | |
CY2023 | dei |
City Area Code
CityAreaCode
|
617 | |
CY2023 | dei |
Local Phone Number
LocalPhoneNumber
|
682-0917 | |
CY2023 | dei |
Security12b Title
Security12bTitle
|
Common Stock, $0.0001 par value per share | |
CY2023 | dei |
Trading Symbol
TradingSymbol
|
AMLX | |
CY2023 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
CY2023 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
CY2023 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
CY2023 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2023 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2023 | dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | |
CY2023 | dei |
Entity Small Business
EntitySmallBusiness
|
false | |
CY2023 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2023 | dei |
Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
|
true | |
CY2023 | dei |
Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
|
false | |
CY2023 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2023Q2 | dei |
Entity Public Float
EntityPublicFloat
|
1310000000 | |
CY2024Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
67782139 | |
CY2023 | dei |
Auditor Name
AuditorName
|
Deloitte & Touche LLP | |
CY2023 | dei |
Auditor Location
AuditorLocation
|
Boston, Massachusetts | |
CY2023 | dei |
Auditor Firm
AuditorFirmId
|
34 | |
CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
170201000 | |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
62526000 | |
CY2023Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
201161000 | |
CY2022Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
284419000 | |
CY2023Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
40050000 | |
CY2022Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
15306000 | |
CY2023Q4 | us-gaap |
Inventory Net
InventoryNet
|
38323000 | |
CY2022Q4 | us-gaap |
Inventory Net
InventoryNet
|
9769000 | |
CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
14931000 | |
CY2022Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
10113000 | |
CY2023Q4 | us-gaap |
Assets Current
AssetsCurrent
|
464666000 | |
CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
382133000 | |
CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2686000 | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2611000 | |
CY2023Q4 | us-gaap |
Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
|
719000 | |
CY2022Q4 | us-gaap |
Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
|
719000 | |
CY2023Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
3725000 | |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
5524000 | |
CY2023Q4 | us-gaap |
Inventory Noncurrent
InventoryNoncurrent
|
44957000 | |
CY2023Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
701000 | |
CY2022Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
466000 | |
CY2023Q4 | us-gaap |
Assets
Assets
|
517454000 | |
CY2022Q4 | us-gaap |
Assets
Assets
|
391453000 | |
CY2023Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
22061000 | |
CY2022Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
6257000 | |
CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
57724000 | |
CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
38312000 | |
CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2257000 | |
CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2040000 | |
CY2023Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
82042000 | |
CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
46609000 | |
CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
1980000 | |
CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
4237000 | |
CY2023Q4 | us-gaap |
Liabilities
Liabilities
|
84022000 | |
CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
50846000 | |
CY2022Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
CY2022Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | |
CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
67707432 | |
CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
67707432 | |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
66512011 | |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
66512011 | |
CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
7000 | |
CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
7000 | |
CY2023Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
738177000 | |
CY2022Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
694906000 | |
CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-304949000 | |
CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-354220000 | |
CY2023Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
197000 | |
CY2022Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-86000 | |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
433432000 | |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
340607000 | |
CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
517454000 | |
CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
391453000 | |
CY2023 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
380786000 | |
CY2022 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
22230000 | |
CY2021 | us-gaap |
Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
|
285000 | |
CY2023 | us-gaap |
Revenues
Revenues
|
380786000 | |
CY2022 | us-gaap |
Revenues
Revenues
|
22230000 | |
CY2021 | us-gaap |
Revenues
Revenues
|
285000 | |
CY2023 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
25441000 | |
CY2022 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
2993000 | |
CY2023 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
128187000 | |
CY2022 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
93450000 | |
CY2021 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
44040000 | |
CY2023 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
188356000 | |
CY2022 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
127128000 | |
CY2021 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
38933000 | |
CY2023 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
341984000 | |
CY2022 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
223571000 | |
CY2021 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
82973000 | |
CY2023 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
38802000 | |
CY2022 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-201341000 | |
CY2021 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-82688000 | |
CY2023 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
16155000 | |
CY2022 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
4291000 | |
CY2021 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
36000 | |
CY2021 | amlx |
Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
|
5228000 | |
CY2023 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-660000 | |
CY2022 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-551000 | |
CY2021 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-51000 | |
CY2023 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
15495000 | |
CY2022 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
3740000 | |
CY2021 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-5243000 | |
CY2023 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
54297000 | |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-197601000 | |
CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-87931000 | |
CY2023 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
5026000 | |
CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
774000 | |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
49271000 | |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-198375000 | |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-87931000 | |
CY2023 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.73 | |
CY2022 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-3.39 | |
CY2021 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-13.35 | |
CY2023 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.7 | |
CY2022 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-3.39 | |
CY2021 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-13.35 | |
CY2023 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
67234465 | |
CY2022 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
58495587 | |
CY2021 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
6586349 | |
CY2023 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
69991340 | |
CY2022 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
58495587 | |
CY2021 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
6586349 | |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
49271000 | |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-198375000 | |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-87931000 | |
CY2023 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
188000 | |
CY2022 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-69000 | |
CY2021 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
14000 | |
CY2023 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
95000 | |
CY2022 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-26000 | |
CY2021 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-5000 | |
CY2023 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
283000 | |
CY2022 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-95000 | |
CY2021 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
9000 | |
CY2023 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
49554000 | |
CY2022 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-198470000 | |
CY2021 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-87922000 | |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-66725000 | |
CY2021 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
343000 | |
CY2021 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3136000 | |
CY2021 | us-gaap |
Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Net Of Tax
OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
|
9000 | |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-87931000 | |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-151168000 | |
CY2022 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
239351000 | |
CY2022 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
196379000 | |
CY2022 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
2189000 | |
CY2022 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
21714000 | |
CY2022 | us-gaap |
Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Net Of Tax
OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
|
-95000 | |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-198375000 | |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
340607000 | |
CY2023 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
5725000 | |
CY2023 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
37546000 | |
CY2023 | us-gaap |
Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Net Of Tax
OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
|
283000 | |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
49271000 | |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
433432000 | |
CY2023 | us-gaap |
Profit Loss
ProfitLoss
|
49271000 | |
CY2022 | us-gaap |
Profit Loss
ProfitLoss
|
-198375000 | |
CY2021 | us-gaap |
Profit Loss
ProfitLoss
|
-87931000 | |
CY2023 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
37161000 | |
CY2022 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
21714000 | |
CY2021 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3136000 | |
CY2023 | us-gaap |
Depreciation
Depreciation
|
1088000 | |
CY2022 | us-gaap |
Depreciation
Depreciation
|
487000 | |
CY2021 | us-gaap |
Depreciation
Depreciation
|
52000 | |
CY2023 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
9940000 | |
CY2022 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
2056000 | |
CY2021 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-121000 | |
CY2021 | amlx |
Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
|
5228000 | |
CY2023 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
24744000 | |
CY2022 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
15306000 | |
CY2023 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
73129000 | |
CY2022 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
9769000 | |
CY2023 | us-gaap |
Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
|
-23000 | |
CY2022 | us-gaap |
Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
|
-487000 | |
CY2021 | us-gaap |
Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
|
144000 | |
CY2023 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
4817000 | |
CY2022 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
5221000 | |
CY2021 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
4486000 | |
CY2023 | amlx |
Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
|
1799000 | |
CY2022 | amlx |
Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
|
1635000 | |
CY2023 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
231000 | |
CY2022 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
456000 | |
CY2021 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-125000 | |
CY2023 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
15882000 | |
CY2022 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1854000 | |
CY2021 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
670000 | |
CY2023 | amlx |
Increase Decrease In Accrued Expenses And Deferred Rent
IncreaseDecreaseInAccruedExpensesAndDeferredRent
|
21597000 | |
CY2022 | amlx |
Increase Decrease In Accrued Expenses And Deferred Rent
IncreaseDecreaseInAccruedExpensesAndDeferredRent
|
26052000 | |
CY2021 | amlx |
Increase Decrease In Accrued Expenses And Deferred Rent
IncreaseDecreaseInAccruedExpensesAndDeferredRent
|
8432000 | |
CY2023 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-2041000 | |
CY2022 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-917000 | |
CY2021 | amlx |
Increase Decrease In Accrued Interests Dueto Related Parties
IncreaseDecreaseInAccruedInterestsDuetoRelatedParties
|
-2000 | |
CY2023 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
11919000 | |
CY2022 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-179871000 | |
CY2021 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-74799000 | |
CY2023 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1241000 | |
CY2022 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2526000 | |
CY2021 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
353000 | |
CY2023 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
300826000 | |
CY2022 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
415873000 | |
CY2021 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
49053000 | |
CY2023 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
394120000 | |
CY2022 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
179411000 | |
CY2021 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
3000000 | |
CY2023 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
92053000 | |
CY2022 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-238988000 | |
CY2021 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-46406000 | |
CY2021 | amlx |
Proceeds From Repayments Of Paycheck Protection Program Loan
ProceedsFromRepaymentsOfPaycheckProtectionProgramLoan
|
-263000 | |
CY2022 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
200897000 | |
CY2022 | amlx |
Proceeds From Follow On Offering
ProceedsFromFollowOnOffering
|
231550000 | |
CY2022 | amlx |
Initial Public Offering Cost Paid
InitialPublicOfferingCostPaid
|
2044000 | |
CY2023 | amlx |
Follow On Offering Costs Paid
FollowOnOfferingCostsPaid
|
136000 | |
CY2022 | amlx |
Follow On Offering Costs Paid
FollowOnOfferingCostsPaid
|
803000 | |
CY2021 | amlx |
Proceeds From Issuance Of Convertible Notes Related Parties
ProceedsFromIssuanceOfConvertibleNotesRelatedParties
|
14272000 | |
CY2021 | us-gaap |
Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
|
11887000 | |
CY2021 | amlx |
Issuance Costs Related To Conversion Of Convertible Notes
IssuanceCostsRelatedToConversionOfConvertibleNotes
|
50000 | |
CY2021 | us-gaap |
Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
|
135000000 | |
CY2021 | amlx |
Issuance Costs Related To Issuance Of Series Redeemable Convertible Preferred Stock
IssuanceCostsRelatedToIssuanceOfSeriesRedeemableConvertiblePreferredStock
|
209000 | |
CY2023 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
6994000 | |
CY2022 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
2189000 | |
CY2021 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
343000 | |
CY2023 | amlx |
Withholding Taxes Paid On Stock Based Awards
WithholdingTaxesPaidOnStockBasedAwards
|
3315000 | |
CY2021 | amlx |
Payment Of Deferred Offering Costs
PaymentOfDeferredOfferingCosts
|
2474000 | |
CY2023 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
3543000 | |
CY2022 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
431789000 | |
CY2021 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
158506000 | |
CY2023 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
160000 | |
CY2022 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-65000 | |
CY2021 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
13000 | |
CY2023 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
107675000 | |
CY2022 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
12865000 | |
CY2021 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
37314000 | |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
63245000 | |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
50380000 | |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
13066000 | |
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
170920000 | |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
63245000 | |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
50380000 | |
CY2021 | amlx |
Conversion Of Convertible Notes And Accrued Interest Into Redeemable Convertible Preferred Stock
ConversionOfConvertibleNotesAndAccruedInterestIntoRedeemableConvertiblePreferredStock
|
32548000 | |
CY2023 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
95000 | |
CY2022 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
-26000 | |
CY2021 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
-5000 | |
CY2023 | amlx |
Taxes Withheld On Stock Based Awards Included In Accrued Expenses
TaxesWithheldOnStockBasedAwardsIncludedInAccruedExpenses
|
23000 | |
CY2023 | amlx |
Purchases Of Property And Equipment Included In Accounts Payable
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayable
|
20000 | |
CY2022 | amlx |
Purchases Of Property And Equipment Included In Accounts Payable
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayable
|
98000 | |
CY2021 | amlx |
Purchases Of Property And Equipment Included In Accounts Payable
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayable
|
22000 | |
CY2021 | amlx |
Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
|
967000 | |
CY2022 | amlx |
Right Of Use Assets And Liabilities Upon Asc842 Adoption
RightOfUseAssetsAndLiabilitiesUponAsc842Adoption
|
2201000 | |
CY2022 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
4958000 | |
CY2022 | amlx |
Movement Of Deferred Offering Costs To Equity
MovementOfDeferredOfferingCostsToEquity
|
5457000 | |
CY2022 | amlx |
Follow On Offering Costs Included In Accounts Payable And Accrued Expenses
FollowOnOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
|
136000 | |
CY2022 | amlx |
Conversion Of Preferred Stock To Common Stock Upon Initial Public Offering
ConversionOfPreferredStockToCommonStockUponInitialPublicOffering
|
239351000 | |
CY2023 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
6389000 | |
CY2022 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
27000 | |
CY2023 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Business</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amylyx Pharmaceuticals, Inc., together with its wholly owned subsidiaries, known as Amylyx or the Company, is a commercial-stage biotechnology company with a mission to end the suffering caused by neurodegenerative diseases. The Company is pursuing amyotrophic lateral sclerosis, or ALS, as its first indication and is focused on the development and potential commercialization of AMX0035 for ALS globally. AMX0035 is approved by the U.S. Food and Drug Administration, or the FDA, and marketed as RELYVRIO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine) for the treatment of ALS in adults in the U.S. AMX0035 is also approved with conditions by Health Canada and marketed as ALBRIOZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the treatment of ALS in Canada. The Company continues to focus on the completion of its global PHOENIX Phase 3 clinical trial, which will provide additional data on the efficacy and safety profile of AMX0035 in people living with ALS, and is also developing AMX0035 in other neurodegenerative diseases. AMX0035 was designed to target endoplasmic reticulum, or ER, stress and mitochondrial dysfunction, two connected central pathways that can lead to neurodegeneration. The Company is further investigating AMX0035 in diseases where ER and mitochondrial stress are implicated, including progressive supranuclear palsy, or PSP, and Wolfram syndrome, or WS. The Company dosed the first participant in the HELIOS trial, a Phase 2 trial of AMX0035 for the treatment of WS, in April 2023. The Company dosed the first participant in the ORION trial, a global, pivotal Phase 3 trial of AMX0035 for the treatment of PSP, in December 2023. The Company is also advancing additional drug candidates for neurodegenerative diseases including AMX0114, an antisense oligonucleotide, targeting Calpain-2, a key protein in axonal degeneration, among others.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, but not limited to, the outcome of preclinical studies and clinical trials, market acceptance and the successful commercialization of its approved products ALBRIOZA, which received marketing authorization with conditions in Canada in June 2022, and RELYVRIO, which was approved by the FDA in the U.S. in September 2022, potential difficulties with or delays in timing with respect to regulatory approval processes, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, ability to secure additional capital to fund operations, and risks associated with the economic challenges caused by global health crises such as the COVID-19 pandemic and economic uncertainty in various global markets caused by geopolitical instability and conflict. The Company and its contractors may experience disruptions in supply of items that are essential for its research and development and commercial activities, including, for example, raw materials and bulk drug substances that the Company imports from Europe and Canada used in the manufacturing of AMX0035, and any additional or future product candidates.</span></p> | |
CY2023 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates—</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. Management’s estimation process often may yield a range of potentially reasonable estimates and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: gross-to-net, or GTN, adjustments; recoverability of inventories, including those produced in preparation for product launches; accrued expenses; stock option valuations; valuation allowance for deferred tax assets and research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> | |
CY2023 | amlx |
Incremental Costs Expenses
IncrementalCostsExpenses
|
0 | |
CY2022 | amlx |
Incremental Costs Expenses
IncrementalCostsExpenses
|
0 | |
CY2021 | amlx |
Incremental Costs Expenses
IncrementalCostsExpenses
|
0 | |
CY2023Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
|
0 | |
CY2023 | amlx |
Cash And Cash Equivalents Maturity Date Description
CashAndCashEquivalentsMaturityDateDescription
|
The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. | |
CY2023Q4 | us-gaap |
Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
|
700000 | |
CY2022Q4 | us-gaap |
Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
|
700000 | |
CY2023 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk—</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments and accounts receivable, net. The Company maintains its cash in financial institutions that it believes have high credit quality. The Company has not experienced any losses on such accounts, and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s accounts receivable, net represents amounts due to the Company from customers. Amylyx performs ongoing credit evaluations of its customers and generally does not require collateral. The Company monitors its exposure and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">records a reserve against uncollectible amounts as necessary. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">Three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">four</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customers individually accounted for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of total gross product revenue in 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> revenue was recognized in 2021. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">Three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customers individually accounted for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of total accounts receivable, net as of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p> | |
CY2021 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
0 | |
CY2023 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | |
CY2022 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | |
CY2023 | amlx |
Sales And Marketing Costs Policy Policy Textblock
SalesAndMarketingCostsPolicyPolicyTextblock
|
<p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales and Marketing Costs—</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales and marketing expenses consist primarily of wages and benefits for sales and marketing personnel, professional and consulting fees, administrative travel expenses, and marketing and advertising costs such as marketing literature, promotional activities, conferences and seminars and branding. Sales and marketing, and advertising costs are expensed as incurred and included in selling, general and administrative expenses in the accompanying consolidated statements of operations. The Company considers advertising costs as expenses related to the promotion of the Company's commercial products. For the years ended December 31, 2023 and 2022, advertising costs were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. The Company did not have commercial products in 2021.</span></p> | |
CY2023 | us-gaap |
Advertising Expense
AdvertisingExpense
|
9500000 | |
CY2022 | us-gaap |
Advertising Expense
AdvertisingExpense
|
4400000 | |
CY2023 | amlx |
Gain Contingency Recorded Amount
GainContingencyRecordedAmount
|
0 | |
CY2023 | us-gaap |
Loss Contingency Loss In Period
LossContingencyLossInPeriod
|
0 | |
CY2022 | us-gaap |
Loss Contingency Loss In Period
LossContingencyLossInPeriod
|
0 | |
CY2022 | amlx |
Gain Contingency Recorded Amount
GainContingencyRecordedAmount
|
0 | |
CY2023 | amlx |
Revenue From Contract With Customer Excluding Assessed Tax Gross
RevenueFromContractWithCustomerExcludingAssessedTaxGross
|
431433000 | |
CY2022 | amlx |
Revenue From Contract With Customer Excluding Assessed Tax Gross
RevenueFromContractWithCustomerExcludingAssessedTaxGross
|
27104000 | |
CY2023 | amlx |
Gross To Net Adjustments
GrossToNetAdjustments
|
-50647000 | |
CY2022 | amlx |
Gross To Net Adjustments
GrossToNetAdjustments
|
-4874000 | |
CY2023 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
380786000 | |
CY2022 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
22230000 | |
CY2022 | amlx |
Gross To Net Adjustments Reserve Provision Related To Current Period Sales
GrossToNetAdjustmentsReserveProvisionRelatedToCurrentPeriodSales
|
4874000 | |
CY2022 | amlx |
Gross To Net Adjustments Reserve Credits And Payments Made
GrossToNetAdjustmentsReserveCreditsAndPaymentsMade
|
-570000 | |
CY2022Q4 | amlx |
Gross To Net Adjustments Reserve
GrossToNetAdjustmentsReserve
|
4304000 | |
CY2023 | amlx |
Gross To Net Adjustments Reserve Provision Related To Current Period Sales
GrossToNetAdjustmentsReserveProvisionRelatedToCurrentPeriodSales
|
51163000 | |
CY2023 | amlx |
Gross To Net Adjustments Reserve Adjustments Related To Prior Period Sales
GrossToNetAdjustmentsReserveAdjustmentsRelatedToPriorPeriodSales
|
-516000 | |
CY2023 | amlx |
Gross To Net Adjustments Reserve Credits And Payments Made
GrossToNetAdjustmentsReserveCreditsAndPaymentsMade
|
-35789000 | |
CY2023Q4 | amlx |
Gross To Net Adjustments Reserve
GrossToNetAdjustmentsReserve
|
19162000 | |
CY2022 | us-gaap |
Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
|
0 | |
CY2023 | us-gaap |
Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
|
0 | |
CY2022 | us-gaap |
Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
|
0 | |
CY2023 | us-gaap |
Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
|
0 | |
CY2023Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
|
4996000 | |
CY2023Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
|
3000 | |
CY2022Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
|
70484000 | |
CY2022Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
|
71000 | |
CY2023Q4 | amlx |
Debt Securities Available For Sale Number Of Positions
DebtSecuritiesAvailableForSaleNumberOfPositions
|
11 | |
CY2023Q4 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
|
1 | |
CY2023Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
53144000 | |
CY2022Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
7151000 | |
CY2023Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
18945000 | |
CY2022Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
1681000 | |
CY2023Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
11191000 | |
CY2022Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
937000 | |
CY2023Q4 | amlx |
Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
|
83280000 | |
CY2022Q4 | amlx |
Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
|
9769000 | |
CY2023 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
2700000 | |
CY2023 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
3300000 | |
CY2022 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
400000 | |
CY2021 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
0 | |
CY2023Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
4314000 | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
3151000 | |
CY2023Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1628000 | |
CY2022Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
540000 | |
CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2686000 | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2611000 | |
CY2023Q4 | amlx |
Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
|
12625000 | |
CY2022Q4 | amlx |
Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
|
8424000 | |
CY2023Q4 | amlx |
Accrued Benefits And Incentive Compensation
AccruedBenefitsAndIncentiveCompensation
|
16790000 | |
CY2022Q4 | amlx |
Accrued Benefits And Incentive Compensation
AccruedBenefitsAndIncentiveCompensation
|
15231000 | |
CY2023Q4 | amlx |
Accrued Manufacturing
AccruedManufacturing
|
1652000 | |
CY2022Q4 | amlx |
Accrued Manufacturing
AccruedManufacturing
|
4596000 | |
CY2023Q4 | amlx |
Accrued Consulting And Other Professional Fess
AccruedConsultingAndOtherProfessionalFess
|
6506000 | |
CY2022Q4 | amlx |
Accrued Consulting And Other Professional Fess
AccruedConsultingAndOtherProfessionalFess
|
4116000 | |
CY2023Q4 | amlx |
Rebates And Other Gross To Net Adjustments
RebatesAndOtherGrossToNetAdjustments
|
16063000 | |
CY2022Q4 | amlx |
Rebates And Other Gross To Net Adjustments
RebatesAndOtherGrossToNetAdjustments
|
3582000 | |
CY2023Q4 | amlx |
Royalty Payable
RoyaltyPayable
|
3111000 | |
CY2022Q4 | amlx |
Royalty Payable
RoyaltyPayable
|
1358000 | |
CY2023Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
977000 | |
CY2022Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1005000 | |
CY2023Q4 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
57724000 | |
CY2022Q4 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
38312000 | |
CY2023 | amlx |
Transfer Of Levels Of Investment Securities Fair Value Assets Description
TransferOfLevelsOfInvestmentSecuritiesFairValueAssetsDescription
|
The Company has not transferred any investment securities between the classification levels | |
CY2023 | us-gaap |
Lessee Operating Lease Description
LesseeOperatingLeaseDescription
|
The Company entered into an office space lease at 121 First Street in Cambridge, Massachusetts on January 10, 2022, for 36 months, with an option to extend the lease for 3 years. | |
CY2022Q1 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P36M | |
CY2022Q1 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P3Y | |
CY2022Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
5000000 | |
CY2022Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
5000000 | |
CY2023 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
2175000 | |
CY2022 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
2136000 | |
CY2023 | us-gaap |
Lease Cost
LeaseCost
|
2175000 | |
CY2022 | us-gaap |
Lease Cost
LeaseCost
|
2136000 | |
CY2023Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
3725000 | |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
5524000 | |
CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2257000 | |
CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2040000 | |
CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
1980000 | |
CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
4237000 | |
CY2023Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
4237000 | |
CY2022Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
6277000 | |
CY2023 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
2400000 | |
CY2022 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1400000 | |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
2478000 | |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
1586000 | |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
476000 | |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
4540000 | |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
303000 | |
CY2023Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
4237000 | |
CY2023Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y | |
CY2022Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y10M24D | |
CY2023 | amlx |
Operating Lease Weighted Average Incremental Borrowing Rate
OperatingLeaseWeightedAverageIncrementalBorrowingRate
|
0.073 | |
CY2022 | amlx |
Operating Lease Weighted Average Incremental Borrowing Rate
OperatingLeaseWeightedAverageIncrementalBorrowingRate
|
0.073 | |
CY2021Q4 | us-gaap |
Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
|
37710624 | |
CY2021Q4 | us-gaap |
Temporary Equity Shares Issued
TemporaryEquitySharesIssued
|
37107459 | |
CY2021Q4 | us-gaap |
Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
|
37107459 | |
CY2021Q4 | us-gaap |
Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
|
239351000 | |
CY2021Q4 | us-gaap |
Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
|
416466000 | |
CY2021Q4 | us-gaap |
Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
|
39474330 | |
CY2023Q4 | us-gaap |
Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
|
0 | |
CY2022Q4 | us-gaap |
Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
|
0 | |
CY2023 | amlx |
Common Stock Number Of Voting Rights
CommonStockNumberOfVotingRights
|
1 | |
CY2022 | us-gaap |
Dividends
Dividends
|
0 | |
CY2022Q4 | us-gaap |
Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
|
0 | |
CY2023 | us-gaap |
Dividends
Dividends
|
0 | |
CY2023Q4 | us-gaap |
Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
|
0 | |
CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | |
CY2023Q4 | amlx |
Common Stock Shares Issued And Outstanding
CommonStockSharesIssuedAndOutstanding
|
67707432 | |
CY2022Q4 | amlx |
Common Stock Shares Issued And Outstanding
CommonStockSharesIssuedAndOutstanding
|
66512011 | |
CY2023Q4 | amlx |
Common Stock Authorized And Reserved For Future Issuance
CommonStockAuthorizedAndReservedForFutureIssuance
|
16189297 | |
CY2022Q4 | amlx |
Common Stock Authorized And Reserved For Future Issuance
CommonStockAuthorizedAndReservedForFutureIssuance
|
12038998 | |
CY2023Q4 | amlx |
Unreserved Common Stock Available For Future Issuance
UnreservedCommonStockAvailableForFutureIssuance
|
216103271 | |
CY2022Q4 | amlx |
Unreserved Common Stock Available For Future Issuance
UnreservedCommonStockAvailableForFutureIssuance
|
221448991 | |
CY2022Q1 | us-gaap |
Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
|
11369369 | |
CY2022Q1 | us-gaap |
Sale Of Stock Price Per Share
SaleOfStockPricePerShare
|
19 | |
CY2022Q1 | us-gaap |
Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
|
196400000 | |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
7697812 | |
CY2022Q4 | us-gaap |
Sale Of Stock Price Per Share
SaleOfStockPricePerShare
|
32 | |
CY2022Q4 | us-gaap |
Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
|
230600 | |
CY2023Q4 | us-gaap |
Share Price
SharePrice
|
29.58 | |
CY2022Q4 | us-gaap |
Share Price
SharePrice
|
20.29 | |
CY2021Q4 | us-gaap |
Share Price
SharePrice
|
7.69 | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0377 | |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0197 | |
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0101 | |
CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y18D | |
CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y25D | |
CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y8M23D | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.7035 | |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.8875 | |
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.8161 | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
19.56 | |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
15.1 | |
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
5.25 | |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
8480950 | |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
13.19 | |
CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y2M12D | |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
201765000 | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
2864696 | |
CY2023 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
29.55 | |
CY2023 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
1010376 | |
CY2023 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
5.66 | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
512022 | |
CY2023 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
19.86 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
9823248 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
18.39 | |
CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y10M24D | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
27639000 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
3877634 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
12.58 | |
CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P7Y | |
CY2023Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
18240000 | |
CY2023Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
5945614 | |
CY2023Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
|
22.17 | |
CY2023 | amlx |
Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm
|
P8Y6M | |
CY2023Q4 | amlx |
Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue
|
9399000 | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
20600000 | |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
14200000 | |
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
6200000 | |
CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
31200000 | |
CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
8800000 | |
CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
1300000 | |
CY2023 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
37161000 | |
CY2022 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
21714000 | |
CY2021 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3136000 | |
CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
400000 | |
CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
0 | |
CY2023 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
37161000 | |
CY2022 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
21714000 | |
CY2021 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3136000 | |
CY2023 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
52263000 | |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-198704000 | |
CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-87904000 | |
CY2023 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
2034000 | |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
1103000 | |
CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
-27000 | |
CY2023 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
54297000 | |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-197601000 | |
CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-87931000 | |
CY2023 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
1219000 | |
CY2023 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
2839000 | |
CY2023 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
1192000 | |
CY2022 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
774000 | |
CY2023 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
5250000 | |
CY2022 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
774000 | |
CY2023 | us-gaap |
Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
|
-224000 | |
CY2023 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
5026000 | |
CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
774000 | |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.033 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.039 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.04 | |
CY2023 | amlx |
Effective Income Tax Rate Reconciliation Tax Credit Research Research And Development Percent
EffectiveIncomeTaxRateReconciliationTaxCreditResearchResearchAndDevelopmentPercent
|
-0.126 | |
CY2022 | amlx |
Effective Income Tax Rate Reconciliation Tax Credit Research Research And Development Percent
EffectiveIncomeTaxRateReconciliationTaxCreditResearchResearchAndDevelopmentPercent
|
0.014 | |
CY2021 | amlx |
Effective Income Tax Rate Reconciliation Tax Credit Research Research And Development Percent
EffectiveIncomeTaxRateReconciliationTaxCreditResearchResearchAndDevelopmentPercent
|
0.015 | |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
|
0.062 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
|
-0.005 | |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
0.021 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
-0.002 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
-0.002 | |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.122 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.255 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.244 | |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.015 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.005 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.019 | |
CY2023 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.093 | |
CY2022 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
-0.004 | |
CY2021 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
-0 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
|
14667000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
|
42673000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
|
8164000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
|
10628000 | |
CY2023Q4 | amlx |
Deferred Tax Assets Capitalized Research And Development Costs
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
|
39297000 | |
CY2022Q4 | amlx |
Deferred Tax Assets Capitalized Research And Development Costs
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
|
18079000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
|
1090000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
|
5721000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
|
8039000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
|
5581000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
3792000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
1804000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
|
10425000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
|
7480000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
85474000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
91966000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
83922000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
90587000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
1552000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
1379000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
-1328000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
-1379000 | |
CY2023Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
1328000 | |
CY2022Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
1379000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
224000 | |
CY2023 | us-gaap |
Tax Credit Carryforward Description
TaxCreditCarryforwardDescription
|
The tax credit carryforwards will expire at various dates beginning in 2035. | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
90587000 | |
CY2021Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
40346000 | |
CY2020Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
18900000 | |
CY2023 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
-6665000 | |
CY2022 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
50241000 | |
CY2021 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
21446000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
83922000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
90587000 | |
CY2021Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
40346000 | |
CY2022Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
1013000 | |
CY2021Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
564000 | |
CY2020Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
349000 | |
CY2023Q4 | amlx |
Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
|
271000 | |
CY2022Q4 | amlx |
Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
|
-32000 | |
CY2023 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
|
925000 | |
CY2022 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
|
481000 | |
CY2021 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
|
215000 | |
CY2023Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
2209000 | |
CY2022Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
1013000 | |
CY2021Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
564000 | |
CY2023 | us-gaap |
Significant Change In Unrecognized Tax Benefits Nature Of Event
SignificantChangeInUnrecognizedTaxBenefitsNatureOfEvent
|
The Company does not expect the amount of unrecognized tax benefits to materially change over next 12 months. | |
CY2023 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
|
0 | |
CY2022 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
|
0 | |
CY2021 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
|
0 | |
CY2022 | us-gaap |
Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
|
0.03 | |
CY2023Q4 | us-gaap |
Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
|
0.05 | |
CY2023 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
2300000 | |
CY2022 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
1200000 | |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
49271000 | |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-198375000 | |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-87931000 | |
CY2023 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
67234465 | |
CY2022 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
58495587 | |
CY2021 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
6586349 | |
CY2023 | us-gaap |
Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
|
2756875 | |
CY2023 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
69991340 | |
CY2022 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
58495587 | |
CY2021 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
6586349 | |
CY2023 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.73 | |
CY2022 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-3.39 | |
CY2021 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-13.35 | |
CY2023 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.7 | |
CY2022 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-3.39 | |
CY2021 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-13.35 | |
CY2023 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6318536 | |
CY2022 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9221247 | |
CY2021 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
44813341 |